While compared with trastuzumab ADC, this anti-HER2 Fab-drug conjugate showed lower potency in cancer cells with low HER2 expression, potentially due to its reduced affinity and half-life, although further in vivo investigations are warranted. This evidence concerns the gene ERBB2 and cancer.